Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients [Seeking Alpha]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Seeking Alpha
Summary Soleno Therapeutics, Inc.'s NDA submission of DCCR for the treatment of patients with PWS accepted by the FDA with Priority Review with a PDUFA date of December 27th of 2024. Before the FDA PDUFA date of DCCR for the treatment of patients with PWS, the FDA plans to hold an advisory panel meeting for this drug. If DCCR is granted U.S. marketing approval, it would be the first approved drug of its kind to target hyperphagia and some other problems associated with PWS. The company had $294.6 million in cash as of June 30th of 2024; Enough cash to fund its operations for at least the next 12 months. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » ISAREE K TIMMS/iStock via Getty Images The last time I spoke about Soleno Therapeutics, Inc. NASDAQ: SLNO ) it was in a Seeking Alpha article entitled “ Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst T
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024GlobeNewswire
- Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.MarketBeat
- Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
SLNO
Earnings
- 11/6/24 - Miss
SLNO
Sec Filings
- 11/19/24 - Form SC
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- SLNO's page on the SEC website